Research Article| Volume 19, ISSUE 1, P27-38, January 1997

Download started.


Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal Glucocorticoid for Allergic Rhinitis

      This paper is only available as a PDF. To read, Please Download here.


      Once-daily mometasone furoate nasal spray (MFNS) is a new intranasal glucocorticoid for the treatment of seasonal allergic rhinitis and perennial rhinitis, and for the prophylaxis of seasonal allergic rhinitis. This paper reviews key findings from the clinical development program for MFNS, comprising more than 20 clinical trials with more than 6000 patients worldwide. MFNS exhibits strong anti-inflammatory activity in vitro and in vivo, and has a rapid onset of action, affording clinically significant symptom relief in 28% of patients within 12 hours of the first dose. Once-daily MFNS is at least as effective as other intranasal glucocorticoids, including twice-daily beclomethasone dipropionate and once-daily fluticasone propionate and budesonide. MFNS is well tolerated and has no detectable effect on the hypothalamic-pituitary-adrenal axis, even at up to 20 times the recommended daily dose. MFNS does not cause atrophy of the nasal mucosa; in fact, prolonged treatment tends to restore the nasal mucosa to a more normal phenotype. The once-daily dosing schedule of MFNS may improve patient compliance, while its high margin of systemic safety and rapid onset of action may enhance patient and physician acceptance


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mygind N
        Glucocorticoids and rhinitis.
        Allergy. 1993; 4: 476-490
        • Meltzer EO
        Today's approach to controlling allergic rhinitis.
        J Respir Dis. 1992; 13 (Suppl 6): S30-S39
        • Naclerio RM
        Allergic rhinitis.
        NEJM. 1991; 325: 860-869
        • Mabry RL
        Glucocorticoids in the management of upper respiratory allergy: The emerging role of steroid nasal sprays.
        Otolaryngol Head Neck Surg. 1992; 107: 855-860
        • Mabry RL
        Glucocorticoids in otolaryngology: Nasal aerosols.
        Otolaryngol Head Neck Surg. 1989; 100: 636-637
        • Rosenthal D
        • Duke E
        A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% versus betamethasone valerate ointment 0.1% in the treatment of psoriasis.
        Curr Ther Res. 1988; 44: 790-801
        • Bressinck R
        • Williams J
        • Peets E
        Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 1.0%, on adrenocortical function in psoriasis patients.
        Today's Ther Trends. 1988; 5: 25-34
        • Medansky RS
        • Bressinck R
        • Cole GW
        Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: Comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
        Curtis. 1988; 42: 480-485
        • Barton BE
        • Jakway JP
        • Smith SR
        • Siegel MI
        Cytokine inhibition by a novel steroid mometasone furoate.
        Immunopharmacol Immunotoxicol. 1991; 13: 251-261
        • Umland SP
        • Narhebne DK
        • Razac BS
        • et al.
        Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+ T cells.
        J Allergy Clin Immunol. 1996; 97 (Abstract): 288
        • Therattil J
        • Chavarria V
        • Cosachov J
        • et al.
        The effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis (SAR).
        Ann Allergy Asthma Immunol. 1997; 78 (Abstract): 129
        • Bronsky EA
        • Pedinoff A
        • Nolop K
        Dose ranging study of the activity and tolerance of mometasone furoate in seasonal allergic rhinitis.
        Allergy. 1996; 50 (Abstract): 191-192
        • Berkowitz RB
        • Nolop RB
        • Mesarina-Wicki BE
        Onset of action of mometasone furoate (Nasonex) nasal spray in seasonal allergic rhinitis.
        J Allergy Clin Immunol. 1997; 99 (and the C93-184 Study Group) (Abstract): S441
        • Hebert JR
        • Nolop K
        • Lutsky B
        Once daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: An active- and placebo-controlled study.
        Allergy. 1996; 51: 569-576
        • Graft D
        • Aaronson D
        • Chervinsky P
        • et al.
        A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray.
        J Allergy Clin Immunol. 1996; 98: 724-731
        • Marazzi P
        • Nolop K
        • Lutsky BN
        Prophylactic use of once-daily mometasone furoate (Nasonex) aqueous nasal spray in patients with seasonal allergic rhinitis.
        J Allergy Clin Immunol. 1997; 99 (and the 193-133 Study Group) (Abstract): S440
        • Drouin M
        • Yang WH
        • Bertrand B
        • et al.
        Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for perenial allergic rhinitis patients.
        Ann Allergy Asthma Immunol. 1996; 77: 153-160
        • Day J
        • Nolop K
        • Lutsky BN
        Comparison of once-daily treatment with mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis.
        J Allergy Clin Immunol. 1997; 99 (Abstract): S441
      1. Nasonex®. Schering-Plough Inc., Kenilworth, New Jersey. Product Information.

        • Brannan MD
        • Seiberling M
        • Cutler DL
        • et al.
        Lack of systemic activity with intranasal mometasone furoate.
        J Allergy Clin Immunol. 1996; 97 (Abstract): 198
        • Brannan MD
        • Herron JM
        • Reidenberg P
        • et al.
        Lack of HPA axis suppression following 36 days of intranasal momentasone furoate.
        Ann Allergy Asthma Immunol. 1997; 78 (Abstract): 154
      2. Data on file, Schering-Plough Research Institute, Schering-Plough Inc., Kenilworth, NJ, 1996.

        • O'Brien F
        • Minshall E
        • Nolop K
        • et al.
        Histological and immunocytochemical assessment by nasal biopsy of mometasone furoate nasal spray in perennial rhinitis.
        J Allergy Clin Immunol. 1997; 99 (Abstract): S498
        • Cramer JA
        • Mattson RH
        • Prevey ML
        • et al.
        How often is medication taken as prescribed? A novel technique.
        JAMA. 1989; 261: 3273-3277